Literature DB >> 15302942

Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.

Almut Scherer1, John Frater, Annette Oxenius, Juliet Agudelo, David A Price, Huldrych F Günthard, Martin Barnardo, Luc Perrin, Bernard Hirschel, Rodney E Phillips, Angela R McLean.   

Abstract

There are significant associations between possession of certain HLA class I alleles and rate of progression to AIDS. Immunological data provide an explanatory mechanism for this relationship. Patients with HLA types associated with rapid disease progression recognize a significantly smaller fraction of their known repertoire of viral epitopes than do patients with HLA types associated with slow progression. Population frequency of HLA types (or supertypes) and their capacity to elicit cytotoxic T lymphocyte responses are also negatively correlated. These data provide an immunological mechanism to explain HLA-related risk of progression to AIDS and emphasize the central role of viral evolution in the pathogenesis of HIV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302942      PMCID: PMC514467          DOI: 10.1073/pnas.0404091101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women.

Authors:  C Costello; J Tang; C Rivers; E Karita; J Meizen-Derr; S Allen; R A Kaslow
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  20 years of HIV science.

Authors: 
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  HIV escape: there and back again.

Authors:  John D Altman; Mark B Feinberg
Journal:  Nat Med       Date:  2004-03       Impact factor: 53.440

4.  Reversion of CTL escape-variant immunodeficiency viruses in vivo.

Authors:  Thomas C Friedrich; Elizabeth J Dodds; Levi J Yant; Lara Vojnov; Richard Rudersdorf; Candice Cullen; David T Evans; Ronald C Desrosiers; Bianca R Mothé; John Sidney; Alessandro Sette; Kevin Kunstman; Steven Wolinsky; Michael Piatak; Jeffrey Lifson; Austin L Hughes; Nancy Wilson; David H O'Connor; David I Watkins
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

5.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

6.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

7.  Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.

Authors:  Yoshiyuki Yokomaku; Hideka Miura; Hiroko Tomiyama; Ai Kawana-Tachikawa; Masafumi Takiguchi; Asato Kojima; Yoshiyuki Nagai; Aikichi Iwamoto; Zene Matsuda; Koya Ariyoshi
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

Authors:  Catherine Fagard; Annette Oxenius; Huldrych Günthard; Felipe Garcia; Michelle Le Braz; Gabriel Mestre; Manuel Battegay; Hansjakob Furrer; Pietro Vernazza; Enos Bernasconi; Amalio Telenti; Rainer Weber; Dominique Leduc; Sabine Yerly; David Price; Sara J Dawson; Thomas Klimkait; Thomas V Perneger; Angela McLean; Bonaventura Clotet; Jose M Gatell; Luc Perrin; Montserrat Plana; Rodney Phillips; Bernard Hirschel
Journal:  Arch Intern Med       Date:  2003-05-26

9.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  38 in total

Review 1.  Novel Imaging Methods for Analysis of Tissue Resident Cells in HIV/SIV.

Authors:  Eirini Moysi; Jacob D Estes; Constantinos Petrovas
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  Role of individual's T-cell immunome in controlling HIV-1 progression.

Authors:  Alba Grifoni; Carla Montesano; Paolo Palma; Marta Giovanetti; Marta Giovannetti; Guido Castelli-Gattinara; Massimo Ciccozzi; Maurizio Mattei; Giorgio Mancino; Alfredo Salerno; Vittorio Colizzi; Massimo Amicosante
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

3.  Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans.

Authors:  Aleksandr Lazaryan; Elena Lobashevsky; Joseph Mulenga; Etienne Karita; Susan Allen; Jianming Tang; Richard A Kaslow
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.

Authors:  Ling Yue; Heather A Prentice; Paul Farmer; Wei Song; Dongning He; Shabir Lakhi; Paul Goepfert; Jill Gilmour; Susan Allen; Jianming Tang; Richard A Kaslow; Eric Hunter
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

5.  Virological and immunological factors associated with HIV-1 differential disease progression in HLA-B 58:01-positive individuals.

Authors:  D R Chopera; M Mlotshwa; Z Woodman; K Mlisana; D de Assis Rosa; D P Martin; S Abdool Karim; C M Gray; C Williamson
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

6.  Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

Authors:  Lucy Dorrell; Hongbing Yang; Beatrice Ondondo; Tao Dong; Kati di Gleria; Annie Suttill; Christopher Conlon; Denise Brown; Patricia Williams; Paul Bowness; Nilu Goonetilleke; Tim Rostron; Sarah Rowland-Jones; Tomás Hanke; Andrew McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.

Authors:  Christian B Willberg; Keith E Garrison; R Brad Jones; Duncan A Meiklejohn; Gerald Spotts; Teri J Liegler; Mario A Ostrowski; Annika C Karlsson; Frederick M Hecht; Douglas F Nixon
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

8.  Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.

Authors:  Anju Bansal; Tiffanie Mann; Sarah Sterrett; Binghao J Peng; Anne Bet; Jonathan M Carlson; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

9.  Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection.

Authors:  David A Price; Tedi E Asher; Nancy A Wilson; Martha C Nason; Jason M Brenchley; Ian S Metzler; Vanessa Venturi; Emma Gostick; Pratip K Chattopadhyay; Mario Roederer; Miles P Davenport; David I Watkins; Daniel C Douek
Journal:  J Exp Med       Date:  2009-04-06       Impact factor: 14.307

10.  No evidence for competition between cytotoxic T-lymphocyte responses in HIV-1 infection.

Authors:  Helen R Fryer; Almut Scherer; Annette Oxenius; Rodney Phillips; Angela R McLean
Journal:  Proc Biol Sci       Date:  2009-09-23       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.